Cargando…
Malnutrition and inflammation status in nonobese patients with inflammatory bowel disease are associated with nonalcoholic fatty liver disease: a retrospective study
BACKGROUND/AIMS: The frequency and details of nonalcoholic fatty liver disease (NAFLD) complications in patients with inflammatory bowel disease (IBD) remain unclear. This study aimed to clarify characteristics of NAFLD in patients with IBD. METHODS: We retrospectively identified and enrolled patien...
Autores principales: | Nagata, Takahiro, Funakoshi, Sadahiro, Morihara, Daisuke, Shakado, Satoshi, Yokoyama, Keiji, Takata, Kazuhide, Tanaka, Takashi, Fukunaga, Atsushi, Yamauchi, Ryo, Fukuda, Hiromi, Matsuoka, Hiroki, Imakiire, So, Sakisaka, Hideto, Matsuoka, Satoshi, Kuno, Nobuaki, Abe, Koichi, Ishibashi, Hideki, Ashizuka, Shinya, Hirai, Fumihito |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Association for the Study of Intestinal Diseases
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626015/ https://www.ncbi.nlm.nih.gov/pubmed/37559192 http://dx.doi.org/10.5217/ir.2023.00035 |
Ejemplares similares
-
Resolution of Laryngeal Ulceration with Prednisolone Therapy in a Patient with Crohn's Disease
por: Ko, Yi-Ling, et al.
Publicado: (2022) -
Epstein-Barr Virus-positive Intestinal Diffuse Large B-cell Lymphoma in a Japanese Patient with Celiac Disease: First Reported Case and a Literature Review
por: Ishibashi, Hideki, et al.
Publicado: (2021) -
Pretreatment Modified Albumin–Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma
por: Tanaka, Takashi, et al.
Publicado: (2022) -
Role of Serum Proteinase 3 Antineutrophil Cytoplasmic Antibodies in the Diagnosis, Evaluation of Disease Severity, and Clinical Course of Ulcerative Colitis
por: Imakiire, So, et al.
Publicado: (2022) -
Long-term outcome and eligibility of radiofrequency ablation for hepatocellular carcinoma over 3.0 cm in diameter
por: Tanaka, Takashi, et al.
Publicado: (2023)